Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of RNA CART19 in Refractory/Relapsed Hodgkin Lymphoma
NCT02624258Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Nov 2015
- Primary completion
- Jun 2019
- Modality
- CAR-T Cells, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RNA CART19 cells in Hodgkin lymphoma (HL), sponsored by University of Pennsylvania. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at Month 4. Started Nov 2015; status: terminated.
02
Drugs
RNA CART19 cells
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02624258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02624258.